Infections caused by the latest variant have symptoms including fever, chills, fatigue, cough, congestion and headache.
In another positive development, Pfizer won a bid in a London court to invalidate two of GSK Plc’s GSK patents relating to its respiratory syncytial virus (RSV) vaccine. Also Read: UK Chooses ...
The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that leads to hospitalization or worse for hundreds of thousands of people in the ...
Most people notice this when air pressure changes rapidly, such as when a plane ascends or descends. This happens because the ...
COVID-19 disrupted established patterns of seasonal transmission for several major respiratory Illnesses, with the exception of rhinovirus.
A new COVID variant, XEC, is gaining traction in the U.S. and is estimated to account for up to 13% of cases. The strain is a recombinant of two JN.1 lineage viruses, with new COVID shots expected to ...
Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms ...
Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the ...